Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $652.67 million. The enterprise value is $559.29 million.

Market Cap	652.67M
Enterprise Value	559.29M

Important Dates

The next estimated earnings date is Monday, November 11, 2024, after market close.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 125.03 million shares outstanding. The number of shares has increased by 5.25% in one year.

Current Share Class	125.03M
Shares Outstanding	125.03M
Shares Change (YoY)	+5.25%
Shares Change (QoQ)	+10.10%
Owned by Insiders (%)	9.49%
Owned by Institutions (%)	25.73%
Float	90.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.41

Current Ratio	5.41
Quick Ratio	5.27
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-14.21

Financial Efficiency

Return on equity (ROE) is -850.81% and return on invested capital (ROIC) is -123.55%.

Return on Equity (ROE)	-850.81%
Return on Assets (ROA)	-43.61%
Return on Capital (ROIC)	-123.55%
Revenue Per Employee	n/a
Profits Per Employee	-$754,919
Employee Count	185
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +135.14% in the last 52 weeks. The beta is 1.47, so Humacyte's price volatility has been higher than the market average.

Beta (5Y)	1.47
52-Week Price Change	+135.14%
50-Day Moving Average	5.52
200-Day Moving Average	5.29
Relative Strength Index (RSI)	46.08
Average Volume (20 Days)	3,048,787

Short Selling Information

The latest short interest is 16.68 million, so 13.34% of the outstanding shares have been sold short.

Short Interest	16.68M
Short Previous Month	16.03M
Short % of Shares Out	13.34%
Short % of Float	18.43%
Short Ratio (days to cover)	6.18

Income Statement

Revenue	n/a
Gross Profit	-77.12M
Operating Income	-106.88M
Pretax Income	-105.70M
Net Income	-139.66M
EBITDA	-99.65M
EBIT	-106.88M
Earnings Per Share (EPS)	-$1.29

Full Income Statement

Balance Sheet

The company has $93.56 million in cash and $18.93 million in debt, giving a net cash position of $74.63 million or $0.60 per share.

Cash & Cash Equivalents	93.56M
Total Debt	18.93M
Net Cash	74.63M
Net Cash Per Share	$0.60
Equity (Book Value)	-28.29M
Book Value Per Share	-0.24
Working Capital	78.35M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$80.70 million and capital expenditures -$1.22 million, giving a free cash flow of -$81.92 million.

Operating Cash Flow	-80.70M
Capital Expenditures	-1.22M
Free Cash Flow	-81.92M
FCF Per Share	-$0.66

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.25%
Shareholder Yield	-5.25%
Earnings Yield	-22.03%
FCF Yield	-12.92%

Analyst Forecast

The average price target for Humacyte is $11.50, which is 120.31% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.50
Price Target Difference	120.31%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2